SynthesisJournal of neural transmission (Vienna, Austria : 1996)2019
The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.
Synthesis in Journal of neural transmission (Vienna, Austria : 1996), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pharmacogenomic scores in psychiatry: systematic review of current evidence.Translational psychiatry · 2024Pooled it
- Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Elevated NEGR1 in brain induces anxiety or depression-like phenotypes and synaptic dysfunction.Molecular psychiatry · 2025Article
- Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review.Neuroscience applied · 2025Article
- Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study.The pharmacogenomics journal · 2024Article
- Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression.Neuroscience applied · 2024Article
- Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities.Briefings in bioinformatics · 2023Article
- Clinical utility of polygenic risk scores: a critical 2023 appraisal.Journal of community genetics · 2023Article
- Review
- Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines.Aging · 2023Review
- Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.BMC medicine · 2022Article
- Large-scale genomic analyses reveal insights into pleiotropy across circulatory system diseases and nervous system disorders.Nature communications · 2022Article
- Genetic evidence suggests posttraumatic stress disorder as a subtype of major depressive disorder.The Journal of clinical investigation · 2022Article
- Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study.The pharmacogenomics journal · 2021Article
- Systemic Catecholaminergic Deficiency in Depressed Patients with and without Coronary Artery Disease.Journal of clinical medicine · 2021Article
- Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder.Neural regeneration research · 2021Article
- Article
- Depression-Associated GeneCells · 2020Article
- From Bound Cells Comes a Sound Mind: The Role of Neuronal Growth Regulator 1 in Psychiatric Disorders.Experimental neurobiology · 2020Review
- Transcriptome Changes in Relation to Manic Episode.Frontiers in psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are first-line antidepressants for the treatment of major depressive disorder (MDD). However, treatment response during an initial therapeutic trial is often poor and is difficult to predict. Heterogeneity of response to SSRIs in depressed patients is partly driven by co-occurring somatic disorders such as coronary artery disease (CAD) and obesity. CAD and obesity may also be associated with metabolic side effects of SSRIs. In this study, we assessed the association of CAD and obesity with treatment response to SSRIs in patients with MDD using a polygenic score (PGS) approach. Additionally, we performed cross-trait meta-analyses to pinpoint genetic variants underpinnings the relationship of CAD and obesity with SSRIs treatment response. First, PGSs were calculated at different p value thresholds (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.